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doi:10.1016/j.jfma.2011.11.024Melatonin (N-acetyl-5-methoxytryptamine) is an endogenously produced indoleamine secreted
by the pineal gland and the secretion is suppressed by light. Melatonin is a highly effective
antioxidant, free radical scavenger, and has anti-inflammatory effect. Plenty of evidence
supports the utility of melatonin in adults for cancer, neurodegenerative disorders, and aging.
In children and neonates, melatonin has been used widely, including for respiratory distress
syndrome, bronchopulmonary dysplasia, periventricular leukomalacia (PVL), hypoxiae
ischemia encephalopathy and sepsis. In addition, melatonin can be used in childhood sleep
and seizure disorders, and in neonates and children receiving surgery. This review article
discusses the utility of melatonin in neonates and children.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Melatonin (N-acetyl-5-methoxytryptamine) (Fig. 1), an
endogenously produced indoleamine, is a highly effective
antioxidant, free radical scavenger, and primary circadian
pacemaker.1,2 Melatonin was first identified during the
late 1950s by Lerner et al in the pineal gland.3 Its name
implies melatonin’s first identified functiondits skin-
lightening properties in fish and frog melanocytes. Mela-
tonin is a lipophilic agent that crosses the bloodebraint of Pediatrics, Chang Gung
3 Ta-Pei Road, Niao Sung,
.tw (L.-T. Huang).
ight ª 2012, Elsevier Taiwan LLCbarrier and enters cells rapidly. Melatonin acts as a free
radical scavenger and protects DNA from the damage
induced by free radicals.4 In addition, melatonin stimu-
lates gene expression of antioxidative enzymes.5 More-
over, melatonin has an important stimulatory action in
the immune system, protecting organisms against bacte-
rial and viral infections.1,6
Melatonin has been used clinically in cancer, neurode-
generative diseases, sleep disorders, and ageing in
adults;7,8 however, its utility in children has been rarely
discussed.9e11
Melatonin synthesis and its receptor
In mammals, the melatonin rhythm is generated by an
endogenous circadian clock in the suprachiasmatic nucleus& Formosan Medical Association. All rights reserved.
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Figure 1 Structure of melatonin (N-acetyl-5-methoxy-
tryptamine).
58 Y.-C. Chen et al.of the hypothalamus. The most important factor regulating
the metabolism of the mammalian pineal gland is the light/
dark cycle. Circulating melatonin is synthesized primarily in
the pineal gland, providing circadian and seasonal timing
cues. Melatonin is locally found in various cells, tissues, and
organs, including lymphocytes, bone marrow, the thymus,
the gastrointestinal tract, the skin, the Harderian gland,
and the retina.1,2,4 The production of melatonin also occurs
in invertebrates, bacteria, and plants.12
Melatonin is synthesized from the amino acid precursor
tryptophan, primarily in the pineal gland. At least four
enzymes are known to be involved in this process. Among
them, serotonin N-acetyltransferase is considered the rate-
limiting enzyme in the regulation of melatonin biosynthesis
(Fig. 2). The melatonin half-life in serum varies between
less than 30 min and 60 min. It is metabolized primarily in
the liver and secondarily in the kidney.12
There are two types of membrane-associated melatonin
receptors, MT1 and MT2, which belong to the G-protein-
coupled receptor superfamily, and have been cloned in
mammals. The melatonin MT1 and MT2 membrane-bound
receptors show 60% homology at the amino acid level. A
third membrane-associated receptor, named MT3, has
been described pharmacologically and characterized as
the enzyme quinine reductase 2. This enzyme belongs toFigure 2 Synthesis of melatonin (N-acetyl-5-methoxy-
tryptamine).a group of reductases that participate in the protection
against oxidative stress by preventing electron transfer
reactions of quinones.Pleiotropy of melatonin
Melatonin has pleiotropic bioactivities, including regulation
of the circadian rhythms, reproductive physiology, and
body temperature.1,2 Subsequently, melatonin and its
metabolites were found to have important antioxidant
properties owing to their direct and indirect antioxidant
actions.1,2
Oxygen-derived metabolites, collectively termed reac-
tive oxygen species (ROS), are normally produced in aerobic
organisms. Oxidative stress is defined as an imbalance
between prooxidant and antioxidant forces leading to an
overall prooxidant insult. Melatonin and its byproducts are
capable of scavenging both ROS and reactive nitrogen
species (RNS), including the hydroxyl radical (OH),
hydrogen peroxide (H2O2), singlet oxygen (
1O2), hypo-
chlorous acid (HClO), peroxynitrite anion (ONOOe), and/or
peroxynitrous acid (ONOOH).8
Melatonin also acts as a potent endogenous antioxidant
by scavenging free radicals and upregulating antioxidant
pathways. The activity and expression of antioxidant
enzymes such as superoxide dismutase, glutathione,
catalase, glutathione peroxidase, and glutathione reduc-
tase have been shown to be increased by melatonin, sup-
porting its indirect antioxidant action. Further evidence
of the antioxidant effect of melatonin is provided by
its ability to reduce lipid peroxidation, a degradative
phenomenon involved in the pathogenesis of many
diseases.8
Melatonin may be metabolized not only to kynurenic
acid but also to N1-acetyl-N2-formyl-5-methoxykynuramine
and N1-acetyl-5-methoxykynuramine. These metabolites
are very powerful antioxidants and cyclooxygenase-2
inhibitors. Therefore, they are considered as potential
selective anti-inflammatory agents.1,2,6
Mitochondria are surrounded by outer and inner
membranes, and contain two compartments, the inter-
membrane space and the matrix. Mitochondria play
a critical role in generating energy within the cell through
the electron transport chain. During the process of
biogenesis, mitochondria produce high amounts of ROS and
RNS. In this context, melatonin can stimulate mitochon-
drial biogenesis and increase the efficiency of the electron
transport chain, thereby limiting electron leakage and free
radical generation. In addition, the antioxidant effect of
melatonin and its ability to increase mitochondrial gluta-
thione levels is of great importance for mitochondrial
physiology.13
Melatonin is formed by various leukocytes, including
monocytes, eosinophils, mast cells, T-lymphocytes, NK
cells, and bone marrow cells.14 Leukocytes possess both
MT1/MT2 and nuclear receptors, and this provides the
molecular basis for leukocytes to respond to melatonin.
Melatonin has the capability to regulate inflammatory and
immune processes, thus acting as both an activator and
inhibitor of these responses.1 Melatonin has been sug-
gested to act as an immunomodulator by preventing the
Melatonin and pediatrics 59translocation of nuclear factor-kappa B to the nucleus,
thereby reducing the upregulation of pro-inflammatory
cytokines.6 In addition, melatonin prevents or reduces
the inflammatory-derived activation of phospholipase A2,
lipoxygenase, and cyclooxygenases.1Ontogeny of melatonin function
Melatonin is important in pregnancy and parturition.15
Maternal plasma melatonin levels are elevated during preg-
nancy, reaching a maximum at term, and then returning to
basal levels soon after delivery.15 The placenta expresses
melatonin receptors. Melatonin readily crosses the placenta
and the fetal bloodebrain barrier.16
After birth, the circadian rhythm of melatonin biosyn-
thesis develops between the sixth and eighth week of
life.17 Detectable circadian variations in melatonin level
are observed from the third to sixth month of life, which
coincides chronologically with the development of normal
sleep rhythm. The maximal rise of the amplitude of this
nocturnal melatonin secretion occurs between the fourth
and seventh year of life.18 A role of melatonin in infant
development has also been suggested. Pineal dysfunction
may be associated with deleterious outcomes in infants
and may contribute to an increased prevalence of sudden
infant death syndrome.19 Delayed melatonin production is
evident in infants who had experienced an apparent life-
threatening event.
At puberty, there is a drop in melatonin concentrations,
and thereafter plasma concentrations of melatonin
diminish gradually. In adulthood, melatonin production in
the pineal gland declines progressively with age.Safety profiles and possible side effects of
melatonin
It is worth mentioning that, in pregnant rats, high doses of
melatonin (200 mg/kg/day) from gestational days 6e19 do
not adversely influence the development of rat pups.20 In
the study of Sadowsky et al, a high dose was apparently
without effect on fetal or maternal well-being, and it did
not affect myometrial activity in late gestation.16 Human
studies have shown melatonin toxicity to be remarkably low
with no serious negative side effects even at high doses.21
Safety data are also available from use in children with
various neurologically disabling disorders to improve sleep
patterns and learning disabilities22 and recently from
administration to neonates with sepsis.23
There is general agreement that melatonin therapy has
a remarkably benign safety profile, even when children are
treated with pharmacological doses. However, melatonin is
known to inhibit prostaglandin synthases because prosta-
glandins have important circulatory and endocrine func-
tions in the fetus.24 Few significant adverse events have
been reported in children under melatonin treatment.25,26
There was only one report of increasing seizure activity
in four children with neurologic disabilities treated with
melatonin.27 Table 123,27,36,37,55,62,63,66e69,71,82,83,88e90
summarizes the main clinical utilities of melatonin for
pediatric patients.Melatonin in compromised pregnancy
Pregnancy is a physiological state accompanied by a high
metabolic demand and elevated requirements for oxygen
and hence prone to oxidative stress-induced organ
damages. Furthermore, the placenta is a major source of
oxidative stress because it is rich in polyunsaturated fatty
acids. With advancing human gestation, there is a gradual
favoring of antioxidant activity over oxidant activity.
Preeclampsia and fetal undernutrition are two common
entities of compromised pregnancy.
Melatonin and preeclampsia
Preeclampsia is a multisystem disorder that is unique to
human pregnancy. It happens in 5e10% of pregnancies and
remains a leading cause of maternal and neonatal mortality
and morbidity. In this disorder, lipid peroxide levels in
maternal blood and placental tissue are significantly
increased. In addition, total antioxidant activities are
lowered. Hence, preeclampsia might be considered as
a disorder of oxidative stress in pregnancy.28
Melatonin easily crosses the placenta without being
altered. Also, it can be a desirable component of antioxi-
dant system in human placental mitochondria, significantly
improving its efficiency.29 During normal pregnancy, mela-
tonin works in a variety of ways to serve as a direct free
radical scavenger and an indirect antioxidant, and it
appears to be essential for successful pregnancy. Endoge-
nous melatonin level is significantly decreased in severe
preeclampsia.30 Although most studies for supplement of
melatonin in pregnancy are from animals, recent evidence
has suggested supplements of melatonin as a way of
prevention of preeclampsia in humans.31
Melatonin and fetal undernutrition
Fetal undernutrition resulting in growth restriction in compli-
cated pregnancy is common in obstetric practice. Maternal
undernutrition during pregnancy can result in asymmetric
growth retardation, and it is associated with increased
oxidative stress. There is growing evidence linking slow fetal
growth with the developmental programming of cardiovas-
cular, metabolic diseases, and neuropsychiatric disorders.32
In humans, fetal undernutrition is associated with
significant oxidative stress in small-for-gestational-age
neonates born at term to malnourished mothers.33 Mela-
tonin can increase glutathione peroxidase activity in human
chorion.34 In rats, maternal treatment with melatonin in
undernourished pregnancy improved placental efficiency,
restored birth weight, and increased the expression of
placental manganese superoxide dismutases and catalase.35
Melatonin and clinical conditions related to
premature neonates
Preterm labor itself is a condition susceptible to oxidative
stress injury. Preterm delivery, oxygen use at initial resus-
citation setting, and immature fetal organ development all
make the condition vulnerable to oxidative stress and thus
Table 1 Major applications of melatonin in infant and child disorders.
Condition Study Main results References
Conditions related to prematurity
RDS Melatonin treatment in 24 newborns
with grade III/IV RDS
Reduce proinflammatory cytokines
and nitrite/nitrate level and improve
clinical outcome
36
Melatonin treatment in 110 newborns
with RDS
Clearly had anti-inflammatory
effects
37
BPD Melatonin treatment in 120 newborns
with RDS
No clear beneficial result in
hastening the development of BPD
23
Neonatal events
Neonatal sepsis Melatonin administration in 10 septic
newborns with sepsis
Significant reduction of the levels of
lipid peroxidation products
55
Childhood disorders
Children with sleep disorders
Children with sleep disorders Melatonin in 100 children with sleep
disorders
80% reported improvement of sleep 62
Neurodevelopmentally disabled
children with sleep disorders
Melatonin in 20 children Reduce sleep latency in the studied
children
63
Neurodevelopmentally disabled
children with sleep disorders
Randomized, placebo-controlled trial
of controlled-release melatonin in 50
children
47 reported improvement of sleep
and reduction of family stress
69
Children with autism Controlled-release melatonin in 25
autistic children, an open-labeled study
Effective in improving sleep 66
Children with autism Randomized, placebo-controlled study
in 11 children
Effective in improving sleep 67
Asperger syndrome Open clinical trial in 15 children Effective in decreasing sleep-onset
latency time
68
Autistic spectrum disorder and
fragile X syndrome
Randomized, double-blind, placebo-
controlled study in 12 children
Efficacy and tolerability of
melatonin treatment
71
Children with seizure disorders
Intractable seizure Six children treated with melatonin and
their anticonvulsants
Five reported improvement of
seizure control
82
Children with epilepsy
receiving carbamazepine
Randomized, double-blind, placebo-
controlled study in 31 children
receiving carbamazepine monotherapy
Exert antioxidative effect in children
receiving carbamazepine treatment
83
Melatonin in neurologically
disabled children
Six children, of whom five had a seizure
disorder and one had none
Five reported sleep improvement
but four were found to have
increased seizure frequency
27
Surgical neonates and children
Melatonin in surgical neonates Ten neonates undergoing surgical
procedure received melatonin within
3 h after the operation
Exerts antioxidative activity 88
Melatonin as a premedication
for anesthesia
Double-blind, placebo-controlled study
in 105 children receiving surgery
As effective as midazolam, with
lower incidence of sleep disturbance
89
Melatonin as an alternative
sedative drug
Melatonin for sedation in 40 children
receiving MRI exam
Effective in sedation for MRI exam 90
BPD Z bronchopulmonary dysplasia; MRI Z magnetic resonance imaging; RDS Z respiratory distress syndrome.
60 Y.-C. Chen et al.prone to further tissue injury. Among the organs, the lung
and brain are the two organs most affected.
Melatonin and respiratory distress syndrome and
bronchopulmonary dysplasia
Although hyperoxia is essential for promoting survival
of infants with respiratory distress syndrome (RDS), it
unavoidably leads to excessive production of ROS in therespiratory system. The high concentration of pulmonary
arterial oxygenation, prooxidant drugs, concomitant infec-
tions, or extrapulmonary inflammation can all promote
ROS accumulation and depletion of antioxidants. Improved
survival because of advances in neonatal care has resulted
in an increased number of infants at risk for chronic lung
disease (CLD).
Gitto et al measured the levels of melatonin in 120
newborns diagnosed with RDS and examined whether
Melatonin and pediatrics 61melatonin treatment may delay the development of bron-
chopneumonic dysplasia (BPD). Although no clear beneficial
result was found, they concluded that newborns with CLD
and without melatonin treatment had higher levels of
proinflammatory cytokines than those treated with mela-
tonin.23 Similarly, Gitto et al examined whether melatonin
treatment would lower proinflammatory cytokines
[interleukin-6, interleukin-8, and tumor necrosis factor-
a (TNF-a)] and nitrite/nitrate levels in 24 newborns with
respiratory distress syndrome grade III or IV diagnosed
within the first 6 hours of life and concluded that melatonin
treatment reduced the proinflammatory cytokines and
improved the clinical outcome.36
In their later work, Gitto et al examined the proin-
flammatory cytokines (interleukin-6, interleukin-8, and
TNF-a) and the clinical status in 110 preterm newborns with
RDS ventilated before and after treatment with melatonin
and concluded that melatonin treatment clearly had anti-
inflammatory effects.37 In the above studies, the beneficial
actions of melatonin were presumably related to melato-
nin’s antioxidative action.
Periventricular leukomalacia
Periventricular leukomalacia (PVL) is a necrotic lesion of
the periventricular white matter. The periventricular white
matter, due to immaturity of blood vessels and a decrease
in the vessel density, is highly susceptible to damage during
hypoxic-ischemic episodes. In addition, the damage to the
developing white matter is considered to be mediated by
excess release of glutamate, free radical production,
release of cytokines, and iron accumulation. PVL contrib-
utes significantly to neonatal mortality and long-term
neurodevelopmental deficits in premature infants and is
one of the main causes of cerebral palsy.
Evidence of oxidative stress and lipid peroxidation in
premyelinating oligodendrocytes has been shown in autopsy
brains from premature children with PVL, suggesting that
these are important factors in white matter injury.38 Like-
wise, an increase in free radical products in the cerebro-
spinal fluid in premature infants with white matter damage
has also been demonstrated.39
Melatonin, as an antioxidant, may be an effective neuro-
protective treatment for the fetus. Welin et al demonstrated
that post-asphyxia melatonin treatment (20 mg/kg infusion)
attenuated the increase in activated microglia and 8-
isoprostane (a marker of lipid peroxidation) production
and, at the same time, reduced the number of apoptotic cells
in the cerebral white matter in midgestation fetal sheep.40
Kaur et al found that the protective effects of melatonin on
various parameters in the periventricular white matter of
hypoxic neonatal brains were due to its antioxidant proper-
ties.41 Moreover, Hussen et al demonstrated that melatonin,
acting on its receptors and through adenylate cyclase inhi-
bition, is neuroprotective in a newborn mouse model of
excitotoxic white matter lesions, mimicking human PVL.42
Melatonin utility in the neonatal period
Newborns are especially susceptible to oxidative stress,
which can be accounted for by the fact that neonates are(1) easily exposed to high oxygen concentrations, (2) have
infections or inflammation, (3) have reduced antioxidant
defense mechanisms, and (4) have high levels of free iron
that are required for the Fenton reaction and lead to the
production of the highly toxic hydroxyl radical. In this
context, Saugstad coined the phrase ‘oxygen radical
diseases’ of neonatology.43Melatonin and clinical conditions related to
full-term neonates
Neonatal hypoxiceischemic brain injury
Hypoxiaeischemia (HI), an insult resulting from a lack of
oxygen (hypoxia) or a reduced perfusion (ischemia) in
various organs, is a common cause of brain injury in
neonates. Neonatal HI is the major cause of neonatal brain
injury, resulting in cerebral palsy, learning disabilities,
visual field deficits, and epilepsy.44 Mechanistically, cere-
bral HI sets in motion a cascade of biochemical events and
results in mitochondrial dysfunction, oxidative stress,
inflammation, and cell death.45
Carloni et al examined whether melatonin administration
before or after HI in immature rats has an excellent and
long-lasting benefit on ischemic outcomes and found that
melatonin could represent a potentially safe approach to
perinatal brain damage in humans.46 Moreover, they found
that melatonin has long-lasting beneficial effects on HI
occurring during the substantial neurologic developmental
process. Signorini et al demonstrated that HI induces an
increase in desferrioxamine (DFO)-chelatable free iron in
the cerebral cortex, which can induce cerebral oxidative
stress, whereas the cerebral damage by the oxidative stress
may be prevented by melatonin treatment.47 From the
above studies, melatonin may be considered a treatment
modality for reducing the oxidative stress injury at HI and
further prevention of the ongoing neurological injury
process, which may lead to developmental disabilities.
Neonatal sepsis
Sepsis represents a serious problem in newborns, with an
incidence of approximately 1e10 cases per 1000 live births.
Reported mortality rates resulting from sepsis in newborns
are between 30% and 50%.48
To date, many reports are consistent with the involve-
ment of ROS/RNS in neonatal sepsis and its complications.
Batra et al documented increased production of oxygen-
derived reactants in septic neonates.49 In addition, Seema
et al found newborns with sepsis have significantly higher
levels of TNF-a and increased activity of antioxidative
enzymes such as superoxide dismutase and glutathione
peroxidase.50 In line with the “oxygen radical diseases” of
neonates, Kurt et al demonstrated that serum interleukin-
1b, interleukin-6, interleukin-8, and TNF-a are mediators of
inflammation and can be used for the diagnosis and evalu-
ation of the therapeutic efficiency of drugs in the setting of
neonatal sepsis.51
Several clinical reports on melatonin demonstrated its
role in the reduction of oxidative stress in neonates with
62 Y.-C. Chen et al.sepsis, asphyxia, or conditions associated with excessive
ROS production.52e54 Gitto et al had demonstrated that
melatonin was effective in neonates with septicemia by
reducing the levels of lipid peroxidation products, thereby
improving neonates’ clinical status. 55
Neonatal stress
Neonatal stress has been demonstrated as one of the most
important factors affecting lifelong health.56 Neonatal
stress in humans can originate from maternal postpartum
depression, family conflict, or physical abuse.
In a rodent study, Rasmussen et al showed that daily
melatonin supplementation suppressed hypothalamic gene
expression of proopiomelanocortin that encodes adreno-
corticotropic hormone.57 Munoz et al studied 112
newborns, including normal term babies, preterm infants
born before the 38th week, and babies with fetal distress.
They found that neonatal stress can increase nocturnal
melatonin production compared with normal term and
preterm neonates.58 In their subsequent study, Munoz-
Hoyos et al studied 35 neonates admitted to the Neonatal
Unit with RDS and postulated that the high melatonin
concentrations they observed may serve as a mechanism to
protect against oxidative stress.59 Saito et al showed that
melatonin could modulate the activity of the hypothalamo-
pituitary-adrenal (HPA) axis in chicks.60 Melatonin blocked
the enhanced corticosterone concentrations observed after
layers were either exposed to a novel, open field or injec-
ted intracerebroventricularly with corticotropin-releasing
factor. This study provides direct evidence that melatonin
plays a role in the regulation of the stress response in
neonatal chicks. 60
Melatonin in infants and children
Children with sleep disorder
Aside from treatment of insomnia associated with shift
work and jet lag, melatonin has been used to treat various
sleep disorders. Sleep disorders are a common problem in
childhood, with a prevalence of about 25% in typical
preschool and school-aged children.61 Children with neu-
rodevelopmental disabilities are at increased risk of having
a sleep disorder. Melatonin may induce sleep during the
day, when the endogenous levels of melatonin are low;
however, it does not produce additional sleep-promoting
effect when the melatonin levels are adequate. Melatonin
has been administered to neurologically disabled children
to improve their sleep pattern.62,63 The average dose of
melatonin used for disabled children with sleep disorders
ranges from 2 mg to 10 mg.64
Sleep disturbance is common in patients with autistic
spectrum disorders, and melatonin has a specific role for
sleep problems in children with autistic spectrum
disorder.65 One open-label study of controlled-release
melatonin in children with autistic spectrum disorders
documented an improvement in sleep patterns measured
with the Children’s Sleep Habits Questionnaire.66 Garstang
and Wallis found melatonin to be effective for the treat-
ment of sleep difficulties in seven children with autisticspectrum disorders who participated in a randomized,
double-blind, crossover trial.67
With regard to Asperger syndrome, Paavonen et al re-
ported the effectiveness of melatonin in decreasing sleep-
onset latency times and improving associated behavioral
problems in children.68 They found no improvement in
sleep duration; however, they did report a slight increase in
the number of nighttime awakenings.
In a study by Wasdell et al, melatonin was used in 50
children with neurodevelopmental disabilities, including
autistic spectrum disorders. Overall, the therapy improved
the sleep of 47 children and was effective in reducing
family stress.69 Children with neurodevelopmental disabil-
ities who had treatment-resistant, chronic, delayed sleep
phase syndrome and impaired sleep maintenance showed
improvement in melatonin therapy. 69
Sleep problems are reported in up to 77% of children
with fragile X syndrome.70 In this regard, Wirojanan et al
demonstrated for the first time, a beneficial effect of
melatonin in fragile X syndrome patients.71Childhood seizure disorders
Melatonin has been shown to have antiepileptic activity in
animal studies using different seizure models as well as in
cases of childhood epilepsy.72 Melatonin may specifically
inhibit the N-methyl-D-aspartate subtype of excitatory
glutamatergic receptors in rat striatum.73 Moreover, mela-
tonin increases brain g-aminobutyric acid concentrations
and receptor affinity74 and potentiates brain inhibitory
transmission via g-aminobutyric acid synapses.75 In animal
models, melatonin can inhibit audiogenic76 and electrical
seizures77 as well as reduce convulsions induced by pente-
trazole,78 pilocarpine,79 L-cysteine,80 and kainate.81
Peled et al showed improvement in seizure activity in
five of six children with intractable seizures when mela-
tonin was combined with an antiepileptic drug. In addition,
sleep studies showed a decrease in epileptic activity in two
of the three patients who were monitored during treat-
ment.82 Furthermore, Gupta et al observed that the asso-
ciation of melatonin in the treatment of children with
epilepsy on carbamazepine monotherapy improved their
quality of life.83
Paprocka et al assessed diurnal melatonin secretion in
children with refractory epilepsy as compared to children
without epileptic seizures.84 Analysis of diurnal melatonin
secretion indicated a lower level of the hormone in
patients with refractory epilepsy. They concluded that
a lowered level of melatonin in children with refractory
epilepsy in relation to the control group is the consequence
of the intractable epilepsy or is influenced by antiepileptic
drugs.
Only a few studies have shown direct or indirect pro-
convulsant effects of melatonin. Experimentally, melatonin
enhanced low Mg2þ-induced epileptiform activity in the
hippocampus,85 whereas melatonin antagonists delayed the
onset of pilocarpine-induced seizures.86 Clinically, mela-
tonin has been shown to induce electroencephalographic
abnormalities in patients with temporal lobe epilepsy87
and increase seizure activity in neurologically disabled
children.27
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Gitto et al reported 10 neonates who received lung or
abdomen operations and showed a significant clinical
improvement after administration of melatonin and were
associated with lower levels of interleukin-6 and inter-
leukin-8.88 In the context of pediatric surgery, two clin-
ical trials involving children reported that melatonin was
as effective as midazolam in reducing preoperative
anxiety.89,90 In addition, melatonin was associated with
a more rapid recovery, a reduced incidence of post-
operative delirium, and a lower incidence of sleep
disturbances 2 weeks after surgery when compared with
midazolam.
Potential other applications of melatonin from
evidence of recent animal studies
During the past two decades, numerous animal and
human studies have examined the therapeutic usefulness
of melatonin in different fields of medicine and found
that melatonin has potential therapeutic effects in
ocular, blood, cardiovascular, gastrointestinal, and
rheumatic diseases as an adjuvant agent.91 Of these,
cardiovascular protective effect is the most widely
studied, and prior studies concluded that melatonin may
exert its cardioprotective effect through various mech-
anisms such as scavenging free radicals, increasing nitric
oxide availability, activation of the melatonin receptor
in vascular and endothelial smooth muscle cells to
restore normal vascular tone, and lowering the serum
lipids.92,93
Apart from the utility of melatonin mentioned above,
our previous study demonstrated that melatonin has anti-
hypertensive effects in 4-week-old young rats by addition
of 0.01% melatonin in drinking water for 8 weeks in the
study group.94 The antihypertensive effect of melatonin is
presumed to be through the restoration of the nitric oxide
pathway by reduction of plasma asymmetric dimethylargi-
nine, restoration of plasma L-arginine to asymmetric
dimethylarginine ratio, preservation of renal L-arginine
availability, and attenuation of oxidative stress.94,95
Furthermore, we examined the effect of melatonin treat-
ment in young rats with hepatic encephalopathy by using
the bile duct ligation model, which found that cholestasis in
developing rats may increase oxidative stress and cause
spatial memory deficits and could be prevented by mela-
tonin treatment.96
Melatonin belongs to the group of over-the-counter
medications in the United States and many European
countries. Taking melatonin pills for jet lag or sleep disor-
ders in the United States does not require a physician’s
prescription. However, approval from the Food and Drug
Association is mandatory before clinical use of melatonin in
Taiwanese children. Therefore, more clinical studies to test
the safety in children are needed. Although our previous
studies indicate that melatonin treatment may be consid-
ered in various pediatric disorders for its antioxidative
effect, large-scale, double-blind, randomized, controlled
studies in children are needed before its wide use in pedi-
atric disorders.Conclusions
Melatonin is both a potent free radical scavenger and
a broad-spectrum antioxidant. Melatonin also possesses the
capability to modulate inflammation and increase mito-
chondrial biogenesis. It seems likely that melatonin treat-
ment might give useful results in a wide range of childhood
disorders as has been shown for adults. Altogether, these
features make melatonin a potential therapeutic tool to
improve child health.Acknowledgments
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